Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 06, 2015 7:43 AM ET


Company Overview of Biosceptre International Limited

Company Overview

Biosceptre International Limited, a biotechnology company, develops and commercializes antibody technologies for applications in the diagnosis and treatment of cancer. It develops a range of polyclonal, monoclonal, and domain antibodies for use in IVDs, topical therapeutics, in vivo imaging diagnostics, systemic therapeutics, and vaccines. The company was founded in 2000 and is based in North Ryde, Australia.

Suite 3.08

56 Delhi Road

North Ryde, NSW 2113


Founded in 2000


61 2 9889 1202


61 2 9887 4777

Key Executives for Biosceptre International Limited

Chief Executive Officer and Executive Director
Director of Investor Relations
Compensation as of Fiscal Year 2015.

Biosceptre International Limited Key Developments

Biosceptre Announces Positive Phase I Results for BIL-010T to Treat Basal Cell Carcinoma

Biosceptre announced positive results from its Phase I trial to assess the safety and tolerability of BIL-010t (formerly known as BSCT (Anti-nf-P2X(7)) 10% Ointment), a topically administered, highly purified sheep antibody therapy, to treat Basal Cell Carcinoma (BCC). The Phase I trial, conducted in the US, was an open-label, single-arm, multicentre study, to assess safety, tolerability, and levels of anti-drug antibodies in the patients' serum. The study enrolled 21 male and female patients, with a BCC lesion histologically confirmed within the previous four weeks, who self-applied the BIL-010t ointment for 28 days. The results showed that BIL-010t was both safe and well tolerated, with very high levels of patient compliance. The only reported side effect, associated with treatment, was mild to moderate localised skin reactions. Levels of BIL-010t were generally undetectable in patients' blood serum, and gave no evidence of immunogenicity in the majority of patients. Although efficacy was not a prescribed endpoint of the trial, it was noted that 65% of patients (13 out of 20) who completed the study had decreases in the size of their BCC lesions. The reductions ranged from 10% to 56% reduction in the size of the BCC during the course of treatment.

Similar Private Companies By Industry

Company Name Region
NeuClone Pty. Limited Asia
Solvanix Pty Ltd Asia
PharmaSynth Pty Ltd. Asia
Immunexpress Pty Ltd Asia
Vaxxas Pty. Ltd. Asia

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Biosceptre International Limited, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at